Rare disease pharmacy solutions provider Orsini announced on Monday that it is the exclusive specialty pharmacy partner for California-based Ionis Pharmaceuticals' DAWNZERA (donidalorsen).

DAWNZERA is an FDA-approved prophylactic medicine to prevent attacks of hereditary angioedema (HAE) in adult and paediatric patients aged 12 years and older, self-administered via subcutaneous auto-injector.

HAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, stomach, face and/or throat. HAE is estimated to affect more than 7,000 people in the United States. While minor trauma or stress could trigger an attack, swelling often occurs without a known trigger.

Joining Orsini's existing portfolio of HAE therapies, DAWNZERA is designed to reduce patients' production of prekallikrein, which plays a key role in acute HAE attacks.